Pancreatic cancer has become the third leading cause of cancer mortality. Its incidence is rising in parallel with the rise in obesity, and it’s hard to treat: five-year survival still hovers at just 8 to 9 percent. A new study published online in Nature Communications finds early success with a completely new, metabolic approach: reducing tumors’ ability to get rid of excess nitrogen.
The researchers, led by Nada Kalaany, PhD, of Boston Children’s Hospital’s Division of Endocrinology and the Broad Institute of MIT and Harvard, provide evidence that targeting the enzyme arginase 2 (ARG2) can curb pancreatic tumor growth, especially in people who are obese.
“We found that highly malignant pancreatic tumors are very dependent on the nitrogen metabolism pathway,” says Kalaany. …
At age 13, Jack Andraka lost a family friend to pancreatic cancer. At age 15, he developed a diagnostic test for pancreatic cancer that early findings suggest is highly accurate. In this session, Andraka describes his journey, the Johns Hopkins professor who took him on, his fascination with carbon nanotubes and how open access to scientific journals can help people around the world create solutions to problems. The diagnostic itself is in the early phases of testing.